Monitor for further details on the implementation timeline of the share capital amendment, which will affect share count and trading mechanics. The CEO appointment signals leadership continuity but no immediate operational catalyst.
Price Chart
Executive Summary
COSCIENS Biopharma Inc. reported results from its annual general and special meeting held June 17, 2026. All director nominees were re-elected, Deloitte LLP was reappointed as auditor, and shareholders approved a share capital amendment involving a 1:150 consolidation followed by a 50:1 split (net 3:1 reverse split). Additionally, interim CEO Peter H. Puccetti was appointed as permanent full-time President and CEO. The filing contains no financial data and is routine in nature.
Key Facts
- All six director nominees elected with 86.67% to 96.49% support.
- Deloitte LLP reappointed as auditor with 90.44% votes for.
- Share capital amendment approved: 1:150 consolidation then 50:1 split (net 3:1 reverse split) with 84.85% shareholder approval.
- Peter H. Puccetti appointed as permanent full-time President and CEO, effective immediately.
Financial Impact
No financial data reported; share capital amendment authorized but not yet implemented.
Risk Factors
- Share capital amendment may cause short-term trading volatility or confusion.
- Reverse split could signal underlying financial stress, though no financial data supports this.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-029205 |
| Exhibit: ex99-1.htm | 0001493152-26-029205 |
| Document: form6-k.htm | 0001493152-26-029205 |
| Document: 0001493152-26-029205-index-headers.html | 0001493152-26-029205 |
| Document: 0001493152-26-029205-index.html | 0001493152-26-029205 |
| Document: 0001493152-26-029205.txt | 0001493152-26-029205 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 6, 2026 16w ago | 6-K | $7.05 $5.14 | ▲ +27.09% | ▲ +27.94% | $6.10 (+13.48%) |
Jun 18, 2026 18w ago | 6-K | $2.26 $5.75 | ▲ +154.42% | ▲ +154.89% | $6.10 (+169.91%) |
May 12, 2026 24w ago | 6-K | $1.93 $2.03 | ▲ +5.18% | ▲ +5.79% | $6.10 (+216.06%) |
May 8, 2026 24w ago | 6-K | $1.91 $1.97 | ▲ +3.14% | ▲ +3.45% | $6.10 (+219.37%) |
Apr 20, 2026 27w ago | 6-K | $2.03 $1.87 | ▼ −7.88% | ▼ −12.08% | $6.10 (+200.49%) |
Mar 19, 2026 31w ago | EFFECT | $0.8600 $2.03 | ▲ +136.05% | ▲ +128.43% | $6.10 (+609.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers